Three completed cohorts reporting findings in non-small cell lung cancer, breast, and metastatic colorectal cancer from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study were presented in poster sessions during AACR Annual Meeting 2019. In addition, all seven participating pharmaceutical companies renewed their commitment to provide study drugs at no cost. Learn more.
ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.
ASCO is kicking off its advocacy campaign in support of increased funding for federal cancer research. The launch of this year’s advocacy effort comes as Congress is beginning its work to craft Fiscal Year (FY) 2020 appropriations bills. As part of the campaign, ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH) – a $2.5 billion increase from FY 2019 – and $6.5 billion to the National Cancer Institute (NCI).
Taking place September 22-23, 2019 at ASCO Headquarters in the Washington, DC metro area, this meeting is a unique opportunity for physician investigators and research staff from all types of oncology research programs to network and collaborate, share best practices, and develop solutions to common challenges with conducting oncology clinical trials. Registration will open May 1. Visit the RCF website to learn more, and to access other helpful resources and tools for research programs.
The Workshop on Development of Tissue-Agnostic, Biomarker-Based Indications, cohosted by ASCO, FDA, and Friends of Cancer Research, is now open for registration. The April 26 full-day event aims to bring together members of various sectors to identify clinical trial designs and strategies that can accelerate drug development based on biomarkers that are agnostic to tumor types. Learn more and register.
On April 10, ASCO will convene some of the nation’s top physicians, advocates and rural health experts for a discussion on the challenges facing Americans living with cancer in rural areas and promising approaches to improve outcomes. This event will explore a wide range of topics, including:
Registration is open for the 4th Annual FDA Clinical Outcome Assessments in Cancer Clinical Trials (COA-CCT) Workshop, which will take place July 12 at the FDA White Oak Campus in Silver Spring, Maryland. The one-day workshop, co-hosted by ASCO and the FDA, brings together international regulators, payers, industry, academia, and patients to advance the science of clinical outcome assessments. Learn more and register.
ASCO is assembling a cohort of its members who are willing to participate in survey-based research projects of ASCO members for non-commercial purposes. The immense knowledge and experience of ASCO’s membership can help to accelerate the development of new insights and findings that may help to improve care and care delivery. Learn how to join today!
In the latest ASCO in Action Podcast, ASCO Chief Medical Officer Dr. Richard L. Schilsky joins ASCO CEO Dr. Clifford A. Hudis to discuss the 2019 Clinical Cancer Advances (CCA) report.
Dr. Schilsky outlines some of the most exciting research findings from the past year and highlights the Advance of the Year – progress in the treatment of rare cancers. He also discusses the debut of ASCO’s Research Priorities to Accelerate Progress Against Cancer.